



ELAHERE[®] (mirvetuximab soravtansine-gynx) Injectable
Medication Precertification Request

Page 1 of 1

(All fields must be completed and legible for precertification review.)

Aetna Precertification Notification
 Phone: **1-866-752-7021** (TTY: **711**)
 FAX: **1-888-267-3277**

For Medicare Advantage Part B:
 Please Use Medicare Request Form

Please indicate: Start of treatment: Start date ____ / ____ / ____
 Continuation of therapy, Date of last treatment ____ / ____ / ____

Precertification Requested By: _____ **Phone:** _____ **Fax:** _____

A. PATIENT INFORMATION					
First Name:		Last Name:		DOB:	
Address:			City:	State:	ZIP:
Home Phone:	Work Phone:	Cell Phone:		Email:	
Patient Current Weight: ____ lbs or ____ kgs Patient Height: ____ inches or ____ cms				Allergies:	
B. INSURANCE INFORMATION					
Aetna Member ID #: _____		Does patient have other coverage? <input type="checkbox"/> Yes <input type="checkbox"/> No			
Group #: _____		If yes, provide ID#: _____		Carrier Name: _____	
Insured: _____		Insured: _____			
Medicare: <input type="checkbox"/> Yes <input type="checkbox"/> No If yes, provide ID #:			Medicaid: <input type="checkbox"/> Yes <input type="checkbox"/> No If yes, provide ID #:		
C. PRESCRIBER INFORMATION					
First Name:		Last Name:		(Check One): <input type="checkbox"/> M.D. <input type="checkbox"/> D.O. <input type="checkbox"/> N.P. <input type="checkbox"/> P.A.	
Address:			City:	State:	ZIP:
Phone:	Fax:	St Lic #:	NPI #:	DEA #:	UPIN:
Provider Email:		Office Contact Name:		Phone:	
Specialty (Check one): <input type="checkbox"/> Oncologist <input type="checkbox"/> Other: _____					
D. DISPENSING PROVIDER/ADMINISTRATION INFORMATION					
Place of Administration:			Dispensing Provider/Pharmacy: <i>Patient Selected choice</i>		
<input type="checkbox"/> Self-administered <input type="checkbox"/> Physician's Office			<input type="checkbox"/> Physician's Office <input type="checkbox"/> Retail Pharmacy		
<input type="checkbox"/> Outpatient Infusion Center Phone: _____			<input type="checkbox"/> Specialty Pharmacy <input type="checkbox"/> Other		
Center Name: _____			Name: _____		
<input type="checkbox"/> Home Infusion Center Phone: _____			Address: _____		
Agency Name: _____			Phone: _____ Fax: _____		
<input type="checkbox"/> Administration code(s) (CPT): _____			TIN: _____ PIN: _____		
Address: _____					
E. PRODUCT INFORMATION					
Request is for: <input type="checkbox"/> Elahere (mirvetuximab soravtansine-gynx) Dose: _____ Frequency: _____					
F. DIAGNOSIS INFORMATION - Please indicate primary ICD code and specify any other where applicable.					
Primary ICD Code: _____		Secondary ICD Code: _____		Other ICD Code: _____	
G. CLINICAL INFORMATION - Required clinical information must be completed in its entirety for all precertification requests.					
For Initiation Requests (clinical documentation required for all requests):					
Please select the diagnosis: <input type="checkbox"/> Epithelial ovarian cancer <input type="checkbox"/> Fallopian tube cancer <input type="checkbox"/> Primary peritoneal cancer <input type="checkbox"/> Other					
Please indicate the requested regimen: <input type="checkbox"/> Single agent <input type="checkbox"/> In combination with bevacizumab (Avastin) <input type="checkbox"/> Other					
<input type="checkbox"/> Yes <input type="checkbox"/> No <input type="checkbox"/> Unknown Does the patient have folate receptor-alpha positive disease?					
<input type="checkbox"/> Yes <input type="checkbox"/> No Does the patient have platinum-resistant disease?					
<input type="checkbox"/> Yes <input type="checkbox"/> No Has the patient received at least one prior systemic therapy?					
For Continuation Requests (clinical documentation required for all requests):					
<input type="checkbox"/> Yes <input type="checkbox"/> No Is there evidence of unacceptable toxicity or disease progression while on the current regimen?					
H. ACKNOWLEDGEMENT					
Request Completed By (Signature Required): _____				Date: ____ / ____ / ____	
Any person who knowingly files a request for authorization of coverage of a medical procedure or service with the intent to injure, defraud or deceive any insurance company by providing materially false information or conceals material information for the purpose of misleading, commits a fraudulent insurance act, which is a crime and subjects such person to criminal and civil penalties.					

The plan may request additional information or clarification, if needed, to evaluate requests.